Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
N/A
Complex pathophysiological interactions among obesity, metabolic risk facto...
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
N/A
The purpose of the study is to estimate the incidence of below-knee lower e...
Status
Completed
Location
Multiple Locations
Start Date
2016-02-15
Trial ID
NCT02857764
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
PHASE4
The aim of this project is to identify subgroups of patients with type 2 di...